

Dr. William Wierda

President & CEO

CLL Global Research Foundation

Jane and John Justin Distinguished Chair in Leukemia
Research in Honor of Dr. Elihu Estey

Executive Medical Director

The University of Texas MD Anderson Cancer Center



• CHRONIC LYMPHOCYTIC LEUKEMIA •

Dr. Catherine Wu

Chief in the Division of Transplant and Cellular Therapy
Dana-Farber Cancer Institute



• CHRONIC LYMPHOCYTIC LEUKEMIA •

WHAT'S NEW IN CLL?



10 October 2025

William G. Wierda MD, PhD

Professor of Medicine

Section Head, CLL

Department of Leukemia

U.T. M.D. Anderson Cancer Center

Houston, TX USA



2024 / 2025 MEETINGS

American Society of Hematology
ASH 2024 (Dec)

European Hematology Association
2025 (June)

American Society of Clinical Oncology
2025 (June)

International Workshop on CLL
iwCLL 2025 (Sept)




2025 HOT TOPICS

- **Optimal first-line maintenance**
 - Second generation BTKi choice
- **Optimal first-line targeted combination treatment**
 - VEN+OBIN standard of care
 - Doublet vs triplet – AV/AVO (Europe has Ibr+Ven)
 - PVO promising results
 - Sonrotoclax + Zanubrutinib (preliminary data) – CELESTIAL STUDY
- **Pirtobrutinib after prior cBTKi – activity in earlier lines of treatment (cBTKi naïve, first-line) ?**
- **CD19-CAR-T (Liso-cel) + Ibrutinib**
- **BTK-degraders in development – NX5948; BGB-16673; ABBV101**
- **Epcoritimab (CD20xCD3 bispecific) for CLL and RT**



MEETING UPDATE

American Society of Hematology
ASH 2025




THANK YOU

William G. Wierda MD,PhD

713-745-0428

wwierda@mdanderson.org



2025

Precision Oncology of CLL

